Benard, Brooks A. http://orcid.org/0000-0001-7154-744X
Leak, Logan B. http://orcid.org/0000-0002-7000-9612
Azizi, Armon
Thomas, Daniel http://orcid.org/0000-0002-0837-1231
Gentles, Andrew J. http://orcid.org/0000-0002-0941-9858
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5T32CA9302-40, 5T32CA9302-40, 1R01CA251331)
Blavatnik Family Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Ludwig Institute for Cancer Stem Cell Research and Medicine Leukemia & Lymphoma Society
Article History
Received: 12 May 2021
Accepted: 17 November 2021
First Online: 13 December 2021
Competing interests
: R.M. is on the Board of Directors of BeyondSpring Inc., and Scientific Advisory Boards of Coherus BioSciences, Kodikaz Therapeutic Solutions Inc., and Zenshine Pharmaceuticals. R.M. is an equity holder and founder of CircBio Inc. and Pheast Therapeutics Inc.. R.M. is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences, Inc. The numbers and titles of the awarded patents related to CD47 are as follows: U.S. Patent No. 8,562,997 “<i>Methods of Treating Acute Myeloid Leukemia by Blocking CD47”</i>; U.S. Patent No. 8,709,7429; 9,193,955; 9,796,781; 10,662,242 “<i>Markers of Acute Myeloid Leukemia Stem Cells”</i>; U.S. Patent No. 8,758,750 “<i>Synergistic Anti-CD47 Therapy for Hematologic Cancers”</i>; U.S. Patent No. 9,017,675; 9,382,320 “<i>Humanized and Chimeric Monoclonal Antibodies to CD47”</i>; U.S. Patent No. 9,399,682; 9,493,575; 9,605,0769,611,329; 9,624,305; 9,765,143; 10,640,561 “<i>Methods of Manipulating Phagocytosis Mediated by CD47”</i>; U.S. Patent No. 9,623,079 “<i>Methods for Achieving Therapeutically Effective Doses of Anti-CD47 Agents for Treating Cancer”</i>; U.S. Patent No. 10,087,257; 10,487,150 “<i>SIRP Alpha-Antibody Fusion Proteins”</i>; U.S. Patent No. 10,301,387 “<i>Methods for Achieving Therapeutically Effective Doses of Anti-CD47 Agents”</i>. The numbers and titles of current patent applications related to CD47 are as follows: US-2017210803 “<i>Treatment of Cancer with Combinations of Immunoregulatory Agents”</i>; US-2020048369 “<i>Modified Immunoglobulin Hinge Regions to Reduce Hemagglutination”</i>; US-2020147212 “<i>Dosing Parameters for CD47 Targeted Therapies in Hematologic Malignancies”</i>; PCT/US2021/024937 “<i>Pharmaceutical Formulation of Hu5F9-G4 for Human Therapeutic Use”</i>. The remaining authors have no competing interests to disclose.